

West Virginia Medicaid Drug Utilization Review Board Minutes

May 27, 2020

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance;

Members:

K.C. Lovin, PA-C, Chair
Christopher Terpening, PharmD, PhD, Vice Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Myra Chiang, MD
Kate Forman, PharmD
Phillip Galapon, MD
David Gloss, MD
Michael Lonsinger, PharmD
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS
John Vanin, MD

Members Absent:

Lester Labus, MD

DHHR/BMS Staff:

Brian Thompson, MS, PharmD, Director of Pharmacy Services
Priya Shah, PharmD, Drug Utilization Review Coordinator
Lori Moles, RPh, Staff Pharmacist
Bill Hopkins, Pharmacy operations Manager
Doug Sorvig, Data Analyst

Contract Staff:

Angie Wowczuk, PharmD, Rational Drug Therapy Program (RDTP)
Kim Broedel-Zaugg, RPh, PhD, Marshall University
Jon Willis, Marshall University
Eric Sears, RPh, DXC
Brent Breeding, RPh, Change Healthcare
Jacqueline Hedlund, MD, Change Healthcare

- I. **INTRODUCTIONS**
 - a. K.C. Lovin, Chair, welcomed everyone to the Board meeting at 4:05pm EDT. The DUR Board introduced themselves.

- II. **ARRPOVAL OF MNUTES FROM February 19, 2020 DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting.

III. OLD BUSINESS

none

IV. NEW BUSINESS

a. Speakers

- i. none

b. Updates from April 29, 2020 P & T Committee Meeting

- i. Mr. Breeding presented the updates from the April 29, 2020 P & T meeting for board review. No changes were requested.

c. PDL Prior Authorization Criteria. Attachment A

- i. **Tosymra:** approved as presented
- ii. **Katerzia Suspension:** approved as presented
- iii. **Duaklir Pressair:** approved as presented
- iv. **Ezallor Sprinkle:** approved as presented
- v. **Drizalma Sprinkle:** approved as presented
- vi. **Wakix:** approved as presented
- vii. **Ruconest:** approved as presented
- viii. **GLP1/SGLT2:** approved with changes

V. REPORTS

- a. **DXC Quarterly Report:** Mr. Sears presented an overview of the 2020 First Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B
- b. **Rational Drug Therapy Program:** Dr. Wowczuk presented a review of the prior authorization program for the First Quarter of 2020. Attachment C
- c. **Marshall University Coalition:** Dr. Broedel-Zaugg reported on the progress of retro DUR, the lock in program, number of letters sent/returned, and quarterly newsletter. Attachment D

VI. OTHER BUSINESS

- a. None

VII. NEXT MEETING AND ADJOURNMENT

- VIII. a. The meeting concluded at 5:51pm EDT.
- b. The next meeting will be September 23, 2020 from 4:00pm to 6:00pm and located at WVDHHR.

Population Health Initiatives rankings (top 5 highlighted, ranking # in green)

- ▶ 10 Chronic hepatitis C monitor for appropriate documentation, immunizations, SVR12
- ▶ 2 Patients on Opioids + Benzos + Gabapentin. Letters sent to physicians with >2 patients on this combo ~100 patients
- ▶ 11 COPD dx + Benzos.
- ▶ 1 Opioid dependency dx currently on an opioid
- ▶ 9 Physicians treating patients with Hep C - 2 Medicaid criteria for approval, immunizations and SVR12
- ▶ 3 Opioids + antipsychotics national target Support Act
- ▶ 7 Pediatric antibiotic prescribing QI
- ▶ 12 Methadone for OUD now covered under Medicaid; patients on meds that interfere with QT interval also on methadone
- ▶ 5 Doses of stimulants in adolescents
- ▶ 4 Stimulants and sedatives in combo for sleep disorders
- ▶ 6 Opioids + Benzos (likely covered in #1)
- ▶ 8 PPI use
- ▶ 13 Risperdal in males